About 20% of heart failure patients develop muscle wasting that can progress to life-threatening cachexia, but peptide therapies including ghrelin and myostatin antibodies show potential to halt the decline.
~20% affectedApproximately 1 in 5 ambulatory heart failure patients have sarcopenia, which can be an early treatable stage before progression to dangerous cachexia
What the researchers found
In heart failure patients, muscle wasting (sarcopenia) affects roughly 20% and full-body wasting (cachexia) affects under 10% of ambulatory patients. The review establishes a 'wasting continuum' where skeletal muscle is lost before fat tissue — meaning sarcopenia can be an early warning sign that cachexia is coming.
Multiple peptide-based therapies show potential to halt this wasting process: ghrelin and its analogs stimulate appetite and preserve muscle, growth hormone and testosterone promote anabolism, and myostatin antibodies block the signals that tell muscle to break down. Exercise training, essential amino acids, and electrical muscle stimulation are also discussed as complementary approaches.
Why it matters
Muscle wasting in heart failure is a major cause of disability and death, yet it's often detected too late. This review frames sarcopenia as the treatable early stage of a continuum that leads to irreversible cachexia. The peptide therapies discussed — particularly ghrelin, ghrelin receptor agonists, and myostatin antibodies — represent a new generation of interventions that could stop wasting before it becomes catastrophic. Identifying and treating sarcopenia early in heart failure could fundamentally change patient outcomes.
The numbers in context
~20% sarcopenia prevalence · <10% cachexia prevalence · muscle lost before fat · ghrelin, GH, testosterone, myostatin antibodies reviewed · exercise, amino acids, electrical stimulation also discussed
How the study worked
Narrative review examining the pathophysiology of the sarcopenia-to-cachexia continuum in heart failure. Covers molecular mechanisms of muscle and fat wasting, discusses diagnostic criteria, and reviews potential therapeutic approaches including peptide-based, hormonal, nutritional, and physical interventions.
Who was studied
Review focused on ambulatory heart failure patients experiencing sarcopenia and cachexia
What this study cannot tell us
Narrative review without systematic methodology or new data. The evidence for most discussed therapies comes from small trials or preclinical studies. No head-to-head comparisons between the various therapeutic approaches. The optimal timing and combination of interventions for the wasting continuum have not been established. Published in 2015 — newer data on some therapies (particularly myostatin antibodies) has since emerged.
How to read the evidence
Moderate — well-written narrative review by an established researcher in the field, synthesizing evidence from clinical studies, epidemiological data, and therapeutic trials. The prevalence data and wasting continuum concept are well-supported, though many of the therapeutic approaches discussed have limited clinical evidence.
When this study was published
Published in 2015. The wasting continuum concept remains influential. Since publication, myostatin antibodies and ghrelin receptor agonists have advanced in clinical development, and the topic has gained renewed relevance as GLP-1 drug-induced muscle loss has become a concern.
The bigger picture
The wasting problem in heart failure is getting more attention as the GLP-1 drug revolution raises concerns about muscle loss alongside fat loss. This review's framework — muscle wasting as a treatable continuum rather than an inevitable decline — has influenced how researchers think about preserving lean mass in multiple disease contexts. The peptide therapies discussed (ghrelin agonists, myostatin inhibitors) are now being studied not just for heart failure cachexia but also for cancer wasting, age-related sarcopenia, and GLP-1 drug-induced muscle loss.
Questions still open
- Should all heart failure patients be routinely screened for early sarcopenia to enable earlier intervention?
- Can ghrelin receptor agonists preserve muscle mass in heart failure patients without unworsening cardiovascular function?
- Would combining peptide therapies (e.g., ghrelin + myostatin inhibition) be more effective than single agents for halting the wasting continuum?
Common questions
What's the difference between sarcopenia and cachexia?
How could ghrelin help with muscle wasting in heart failure?
Read the original research
The wasting continuum in heart failure: from sarcopenia to cachexia.
The Proceedings of the Nutrition Society, 74(4), 367-77
Citation
von Haehling, Stephan. (2015). The wasting continuum in heart failure: from sarcopenia to cachexia.. The Proceedings of the Nutrition Society, 74(4), 367-77. https://doi.org/10.1017/S0029665115002438